P34.07 Quantification of BIM mRNA In Circulating Tumor Cells Of Osimertinib-treated Patients with EGFR Mutation-positive Lung Cancer

Osimertinib has a high response rate in untreated epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC) patients. However, currently there are no biomarkers to determine the efficacy of osimertinib. This study investigated whether BIM-γ mRNA expression in circulating tumor cells (CTCs) predicted a poor prognosis of osimertinib treatment in patients with EGFR mutation-positive...